Perspective: E2B transmission
|
|
- Camilla Griffith
- 5 years ago
- Views:
Transcription
1 Perspective: E2B transmission
2 I2B(M) Information about the safety report itself A.1 Report identification A.2 Primary source of information A.3.1 Who sends the information A.3.2 Who receives it Case information B.1 Patient characteristics B.2 Adverse reaction/event B.3 Investigation test and procedures B.4 Information about drugs (both suspect and concomitant) B.5 Narrative case summary and further information 2
3 ICH E2B(M) Guideline Patient Characteristics (B.1) Structured info relevant medical history (B.1.7.1) Relevant past drug history indication (B.1.8) Reported cause(s) of death (B.1.9.2) Autopsy-determined cause(s) of death (B.1.9.4) Relevant medical history parent (B ) Relevant past drug history/parent indication (B ) 3
4 ICH E2B(M) Guideline ICH ICSR Section Reaction(s) (B.2) Reaction in MedDRA terminology (B.2.i.1) ICH ICSR Section Tests and Procedures (B.3) Tests/investigation of the patient (B.3.1) ICH ICSR Section Drug(s) Information (B.4) Indication for use in the case (B.4.k.11) Which reaction(s) recurred? (B.4.k.17.2) ICH ICSR Section Narrative case summary (B.5) Sender s reclassification of reaction (B.5.3) 4
5 ICH EDI Coordination M2 (ESTRI) - the transport vehicle and format definitions M1 Medical Terminology Regulatory Authority Pharmaceutical Company E2b Clinical Safety Data Management: Content of Report 5
6 Regulatory Communications Goal EU FDA MHW INTERNATIONAL STANDARDS EFPIA PhRMA JPMA INDUSTRY 6
7 Coding with MedDRa
8 System Organ Classes Blood and lymphatic Cardiac Congenital, familial and genetic Ear and labyrinth Endocrine Eye Gastrointestinal General and administration site conditions Hepatobiliary Immune Infections and infestations Injury, poisoning and procedural complications Investigations Metabolism and nutrition Musculoskeletal and connective tissue Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nervous Pregnancy, puerperium and perinatal conditions Psychiatric Renal and urinary Reproductive and breast Respiratory, thoracic and mediastinal Skin and subcutaneous tissue Social circumstances Surgical and medical procedures Vascular 8
9 A Multi-Axial Terminology (cont) Primary SOC SOC = Cardiac SOC = Psychiatric SOC = Nervous SOC = Congenital, familial and genetic SOC = Musculoskeletal and connective tissue HLGT = Congenital cardiac HLT = Congenital cardiac valve HLGT = Cognitive and attention and disturbances HLT = Mental retardations HLGT = Mental impairment HLGT = Musculoskeletal and connective tissue congenital HLT = Musculoskeletal and connective tissue of face, neck and jaw congenital PT = Rubinstein-Taybi syndrome 9
10 A Multi-Axial Terminology (cont) 10
11 Legacy Data Conversion Comparing Verbatim to Coded Term Approach Verbatim (R) knee effusion MedDRA PT (based on verbatim) Orig coded term (COSTART) MedDRA PT (based on orig COSTART term) Joint effusion ARTHROSIS Osteoarthritis Common cold Nasopharyngitis INFECTION Infection Periorbital edema Seasonal allergies Periorbital oedema Seasonal allergy FACE EDEMA ALLERGIC REACTION Face oedema Hypersensitivity Skin injury Skin injury SKIN DISORDER Skin disorder 11
12 Legacy data to MedDRA VERBATIM COSTART PT COSTART BODY SYSTEM abnormal liver liver function tests digestive enzymes abnormal abnormal bone marrow depression hematologic and marrow findings lymphatic pseudolymphoma lymphoma like hematologic and reaction lymphatic proteinuria albuminuria metabolism and nutrition bilateral knee swelling edema metabolism and nutrition ards respiratory distress syndrome respiratory MEDDRA PT MEDDRA SOC liver function tests nos investigations abnormal biopsy bone marrow investigations abnormal pseudo lymphoma neoplasms benign, malignant and unspecified (incl cysts and polyps) proteinuria investigations joint swelling acute respiratory distress syndrome musculoskeletal and connective tissue respiratory, thoracic and mediastinal blood blister vesiculobullous rash skin blood blister injury, poisoning and procedural complications (p) skin and subcutaneous tissue (s) abnormal hair growth hair disorder skin hair growth abnormal skin and subcutaneous tissue all over body rash rash skin rash generalised skin and subcutaneous tissue central artery occlusion retinal artery occlusion special senses retinal artery occlusion eye (p) (s) red urine urine abnormality urogenital chromaturia renal and urinary 12
13 NARRATIVE #1 A 75-year-old male developed anginal pain on 21 Feb 2017 resulting in hospitalization while enrolled in a randomized, open-label study. The patient s medical history is significant for triple bypass graft surgery 2014, postural hypotension and stage D prostate carcinoma. On 26 Feb 2017, the patient underwent percutaneous transluminal coronary angioplasty with stent placement in the right coronary and proximal left anterior descending arteries. 13
14 NARRATIVE #1 A 75-year-old male developed anginal pain on 21 Feb 2017 resulting in hospitalization while enrolled in a randomized, open-label study. The patient s medical history is significant for triple bypass graft surgery 2014, postural hypotension and stage D prostate carcinoma. On 26 Feb 2017, the patient underwent percutaneous transluminal coronary angioplasty with stent placement in the right coronary and proximal left anterior descending arteries. 14
15 NARRATIVE #1 A 75-year-old male developed anginal pain on 21 February 2017 resulting in hospitalization while enrolled in a randomized, open-label study. The patient s medical history is significant for triple bypass graft surgery 2014, postural hypotension and stage D prostate carcinoma. On 26 February 2017, the patient underwent percutaneous transluminal coronary angioplasty with stent placement in the right coronary and proximal left anterior descending arteries. 15
16 New terms and re-coding Reported event GVHD (?) GVHD skin GVHD liver GVHD intestine GVHD (as a whole). No diferentiation. Undetermined Skin Liver Intestine 16
17 New terms and re-coding Reported event GVHD (?) GVHD skin GVHD liver GVHD intestine GVHD (as a whole). No diferentiation. Undetermined Skin Liver Intestine 17
18 Version update v18.0 v18.1 v19.0 v19.1 v MedDRA versions per year (March and September) Study A data lok Study B data lock Integrated analysis: MedDRA v20.0 Study C data lock Pharmacovigilance 18
19 Analysis and SMQs
20 Data Retrieval PTC : Multi-Axiality SOC Hepatobiliary Blood and lymphatic Renal and urinary Skin and subcutaneous tissue PT Autoimmune hepatitis Coombs positive haemolytic anaemia Nephritis allergic Stevens-Johnson syndrome 20
21 Data Retrieval PTC : Multi-Axiality SOC HLGT HLT PT Hepatobiliary Hepatic and hepatobiliary Hepatocellular damage and hepatitis NEC Autoimmune hepatitis Blood and lymphatic Haemolyses and related conditions Anaemias haemolytic immune Coombs positive haemolytic anaemia Renal and urinary Nephropathies Glomerulonephritis and nephrotic syndrome Nephritis allergic Skin and subcutaneous tissue Epidermal and dermal conditions Bullous conditions Stevens-Johnson syndrome 21
22 HLT Bullous conditions Acquired epidermolysis bullosa Application site vesicles Benign familial pemphigus Blister Blood blister Bullous impetigo Cervical bulla Dermatitis bullous Dermatitis herpetiformis Diabetic bullosis Epidermolysis Epidermolysis bullosa Erythema multiforme Herpes gestationis Implant site vesicles Infusion site vesicles Injection site vesicles Linear IgA disease Lip blister Oculomucocutaneous syndrome Paraneoplastic pemphigus Pemphigoid Pemphigus Penile blister Porphyria non-acute Pseudoporphyria Staphylococcal scalded skin syndrome Stevens-Johnson syndrome Toxic epidermal necrolysis 22
23 Data Retrieval PTC : Multi-Axiality SOC HLGT HLT PT Hepatobiliary Hepatic and hepatobiliary Hepatocellular damage and hepatitis NEC Autoimmune hepatitis Blood and lymphatic Haemolyses and related conditions Anaemias haemolytic immune Coombs positive haemolytic anaemia Renal and urinary Nephropathies Glomerulonephritis and nephrotic syndrome Nephritis allergic Skin and subcutaneous tissue Epidermal and dermal conditions Bullous conditions Exfoliative conditions Stevens-Johnson syndrome 23
24 HLT Exfoliative conditions Application site exfoliation Dermatitis exfoliative Dermatitis exfoliative generalised Exfoliative rash Eyelid exfoliation Implant site desquamation Injection site desquamation Keratolysis exfoliativa acquired Keratolysis exfoliativa congenital Nikolsky's sign Recall phenomenon Skin exfoliation Infusion site desquamation 24
25 Data Retrieval PTC : Multi-Axiality SOC HLGT HLT PT Hepatobiliary Hepatic and hepatobiliary Hepatocellular damage and hepatitis NEC Autoimmune hepatitis Blood and lymphatic Haemolyses and related conditions Anaemias haemolytic immune Coombs positive haemolytic anaemia Renal and urinary Nephropathies Glomerulonephritis and nephrotic syndrome Nephritis allergic Skin and subcutaneous tissue Epidermal and dermal conditions Bullous conditions Stevens-Johnson syndrome 25
26 Data Retrieval PTC : Multi-Axiality SOC HLGT HLT PT Immune Autoimmune Hepatic autoimmune Blood autoimmune Autoimmune hepatitis Coombs positive haemolytic anaemia Allergic conditions Allergic conditions NEC Nephritis allergic Stevens-Johnson syndrome 26
27 Data Retrieval PTC : Multi-Axiality SOC HLGT HLT PT Hepatobiliary Hepatic and hepatobiliary Hepatocellular damage and hepatitis NEC Autoimmune hepatitis SOC PT Blood and lymphatic Haemolyses and related conditions Anaemias haemolytic immune Coombs positive haemolytic anaemia Hepatobiliary Blood and lymphatic Renal and urinary Autoimmune hepatitis Coombs positive haemolytic anaemia Nephritis allergic Renal and urinary Skin and subcutaneous tissue Nephropathies Epidermal and dermal conditions Glomerulonephriti s and nephrotic syndrome Bullous conditions Nephritis allergic Stevens-Johnson syndrome Skin and subcutaneous tissue Stevens-Johnson syndrome SOC HLGT HLT PT Immune Autoimmune Hepatic autoimmune Autoimmune hepatitis Blood autoimmune Coombs positive haemolytic anaemia Allergic conditions Allergic conditions NEC Nephritis allergic Stevens-Johnson syndrome 27
28 Legacy Data Conversion Comparing Verbatim to Coded Term Approach Verbatim (R) knee effusion MedDRA PT (based on verbatim) Orig coded term (COSTART) MedDRA PT (based on orig COSTART term) Joint effusion ARTHROSIS Osteoarthritis Common cold Nasopharyngitis INFECTION Infection Periorbital edema Seasonal allergies Periorbital oedema Seasonal allergy FACE EDEMA ALLERGIC REACTION Face oedema Hypersensitivity Skin injury Skin injury SKIN DISORDER Skin disorder 28
29 Querying through multiaxiality Nervous Vascular Central nervous haemorrhages and cerebro accidents Central nervous NEC Cerebrovas cular venous and sinus thrombosis Transient cerebro events Traumatic central nervous haemorrhages and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosis Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage and spinal NEC disorder 29
30 Querying through multiaxiality Nervous Vascular Central nervous haemorrhages and cerebro accidents Central nervous NEC Cerebrovas cular venous and sinus thrombosis Transient cerebro events Traumatic central nervous haemorrhages and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosis Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage and spinal NEC disorder 30
31 Querying through multiaxiality Nervous Vascular Central nervous haemorrhages and cerebro accidents Central nervous NEC Cerebrovas cular venous and sinus thrombosis Transient cerebro events Traumatic central nervous haemorrhages and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosis Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage and spinal NEC disorder 31
32 Querying through multiaxiality Nervous Vascular Central nervous haemorrhages and cerebro accidents Central nervous NEC Cerebrovas cular venous and sinus thrombosis Transient cerebro events Traumatic central nervous haemorrhages and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosis Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage and spinal NEC disorder 32
33 Querying through multiaxiality Nervous Vascular Central nervous haemorrhages and cerebro accidents Central nervous NEC Cerebrovas cular venous and sinus thrombosis Transient cerebro events Traumatic central nervous haemorrhages and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosis Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage and spinal NEC disorder 33
34 Nervous Vascular Central nervous haemorrhage s and cerebrovascul ar accidents Central nervous NEC Cerebrov ascular venous and sinus thrombo sis Transient cerebro events Traumatic central nervous haemorrhag es Nervous Vascular Central nervous haemorrhage s and cerebrovascul ar accidents Central nervous NEC Cerebrov ascular venous and sinus thrombo sis Transient cerebro events Traumatic central nervous haemorrhag es and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosi s embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosi s Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage and spinal NEC Cerebrovascul ar disorder and spinal NEC Cerebrovascul ar disorder Nervous Vascular Central nervous haemorrhage s and cerebrovascul ar accidents Central nervous NEC Cerebrova scular venous and sinus thrombosis Transien t cerebro events Traumatic central nervous haemorrhag es Nervous Vascular Central nervous haemorrhage s and cerebrovascul ar accidents Central nervous NEC Cerebrov ascular venous and sinus thrombo sis Transient cerebro events Traumatic central nervous haemorrhag es and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack and spinal necrosis and insufficiency Cerebral infarction Transient ischaemic attack embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosis embolism and thrombosis Cerebral artery embolism Cavernous sinus thrombosi s Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage Nervous haemorrhagic Intraventricular haemorrhage Traumatic intracranial haemorrhage and spinal NEC Cerebrovascul ar disorder and spinal NEC Cerebrovascul ar disorder 34
35 35
36 36
37 37
38 SENSITIVITY / SPECIFICITY Cases of viral hepatitis in a hospital Selection of patients with transaminases > twice the normal value (very sensitive but not specific, too many cases, false positive present) Selection of patients with transaminases > 1000 UI (very specific, but not sensitive, cases lost, false negative present) 38
39 Acute Renal Failure 39
40 Hierarchy Example 40
41 Hierarchy Example 41
42 MedDRA Update Gaithersburg, MD 29 September 2017
43 MedDRA Users Profile As of August 2017 ~5,000 Subscribing organizations (MSSO+JMO) 109 Countries Graph shows type of organizations (self identified) 43
44 MedDRA Users by Region and Top 20 Countries 44
45 2017 MedDRA Subscription Rate Table Note: 76% of all MedDRA users pay no fee or $724 (or less) 45
46 Implemented Changes in MedDRA Rejected Implemented
Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.
Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI 23-24 EKİM 2003 Dr. Tomás Moraleda Agenda 1. What is MedDRA? 2. Conditions before MedDRA 3. MedDRA
More informationMedDRA Basic Concept
MedDRA Basic Concept Pansie Zhang MSD R&D (China) Co., Ltd 23Apr2015 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not
More informationMedDRA Overview A Standardized Terminology
MedDRA Overview A Standardized Terminology Patrick Revelle Director, MedDRA MSSO 6 May 2010 MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations
More informationOverview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)
Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Judy Harrison Chief Medical Officer MedDRA MSSO 22 October 2013 MedDRA Data
More informationWhat s New MedDRA Version 13.1
What s New MedDRA Version 13.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered
More informationWhat s New MedDRA Version March
C What s New MedDRA Version 21.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is registered by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and
More informationMedDRA - International standard for coding safety information. The Golden Triangle
MedDRA - International standard for coding safety information International Pharmacovigilance Conference Moscow, Russia 10 October 2018 Anna Zhao-Wong, MD, PhD MedDRA MSSO The Golden Triangle (MedDRA)
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release draft Based on MedDRA version 7.1 ICH-Endorsed Guide for MedDRA Users on Data Output 18 November 2004 Copyright ICH Secretariat (c/o IFPMA)
More informationData Analysis and Query Building with MedDRA
Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.6 Based on MedDRA Version 16.1 1 October 2013 Disclaimer and Copyright Notice This
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER Release 1.4 Based on MedDRA Version 10.1 ICH-Endorsed Guide for MedDRA Users on Data Output 12 September 2007 Copyright ICH Secretariat (c/o IFPMA)
More informationData Analysis and Query Building with MedDRA
Data Analysis and Query Building with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The
More informationAdvanced MedDRA Coding
Advanced MedDRA Coding MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities
More informationWhat s New MedDRA Version MSSO-DI March 2016
c What s New MedDRA Version 19.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More informationIntroduction to MedDRA
Introduction to MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationWhat s New MedDRA Version March
c What s New MedDRA Version 20.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More informationWhat s New MedDRA Version 18.0
What s New MedDRA Version 18.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More information0301 Anemia Others. Endocrine nutritional and metabolic disorders Others Vascular dementia and unspecified dementia
Certain infectious and parasitic diseases 0101 Intestinal infectious diseases 0102 Tuberculosis 0103 Infections with a predominantly sexual mode of transmission 0104 Viral infections characterized by skin
More informationMedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER
MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output Release 3.14 Based on MedDRA Version 20.1 1 September 2017 Disclaimer and Copyright Notice
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationMedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes
MedDRA 13.0 Review MedDRA Version Changes General Remarks MedDRA Version 13.0 Specific Changes Version 13.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 13.0 Terminology Frequency
More informationWhat Medical Writers Need to Know About MedDRA
What Medical Writers Need to Know About MedDRA Expert Seminar Series Session 2 40 th EMWA Conference, Dublin 6 May 2015 Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO MedDRA was developed under
More informationMedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell
MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 14.0 Terminology Frequency
More informationWhat s New MedDRA Version 15.1
What s New MedDRA Version 15.1 Acknowledgements ACKNOWLEDGEMENTS MedDRA trademark is owned by IFPMA on behalf of ICH. Disclaimer and Copyright Notice This document is protected by copyright and may be
More informationSafety Data Analysis and Query Creation with MedDRA
Safety Data Analysis and Query Creation with MedDRA Anne Kehely & Eva Rump Eli Lilly/MSSO 24th Annual EuroMeeting 26-28 March 2012 Copenhagen, Denmark Insert your logo in this area then delete this text
More informationAttending Physician s Statement
( Form A A This form is used for claiming the social insurance benefit. This form should be completed and signed by the attending physician outpatient and One form for each month, one form for hospitalization
More informationWhat s New MedDRA Version 14.0
What s New MedDRA Version 14.0 Acknowledgements ACKNOWLEDGEMENTS MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Adobe is a registered
More informationAdverse events following immunisation (AEFI) with 2010/2011 seasonal influenza vaccines
Adverse events following immunisation (AEFI) with 00/0 seasonal influenza vaccines Netherlands Pharmacovigilance Centre Lareb 8 juli 0 Goudsbloemvallei 7 57 MH s-hertogenbosch www.lareb.nl info@lareb.nl
More informationEfficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEpisodes of Care Risk Adjustment
Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous
More informationCoding with Confidence
Coding with Confidence Hilary Vass (Global Clinical Dictionary Manager AstraZeneca UK Limited) Tomás Moraleda (Medical Officer MSSO) 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam Netherlands Disclaimer
More informationCoding with MedDRA 4/22/2015
Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities
More informationProposed MedDRA Version 17.0 Complex Changes (July 2013)
Proposed MedDRA Version 17.0 Complex Changes (July 2013) MedDRA User Submitted Requests: 1. Add a new HLT Exserohilum infections to HLGT Fungal infectious disorders Submitter rationale: Adding this HLT
More informationS2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationWHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.
WHO-ART Magnus Wallberg November 24 th 2009 Dar Es Salaam, Tanzania magnus.wallberg@who-umc.org WHO-ART (WHO-Adverse Reaction Terminology) The need for a medical terminology dyspnoea? tinnitus ARDS fever
More informationIntroductory Guide MedDRA Version 15.0
Introductory Guide MedDRA Version 15.0 Acknowledgements Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory
More informationCoding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH
Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationCoding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA
Coding with MedDRA MedDRA trademark is owned by IFPMA on behalf of ICH MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationCoding with MedDRA. Course Overview
Coding with MedDRA MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Course Overview MedDRA background MedDRA s structure, scope,
More informationClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT)
ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT) January 9, 2009 * Required by ClinicalTrials.gov [*] Conditionally required by ClinicalTrials.gov (FDAAA) May be required to comply with
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Lind M, Polonsky W, Hirsch IB, et al. Effect of continuous glucose monitoring vs conventional therapy on glycemic control among patients type 1 diabetes treated multiple daily
More informationIntroductory Guide MedDRA Version 14.0
Introductory Guide MedDRA Version 14.0 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory
More informationCoding with MedDRA 3/2/2017
Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities
More informationSearch for studies: ClinicalTrials.gov Identifier: NCT
ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013 ClinicalTrials.gov ID: NCT00168454 Study Identification Unique Protocol ID: 191622-077 Brief Title: A
More informationA study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
More informationMedDRA: Safety Data Analysis and SMQs
MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
More informationBest practices in VeDDRA coding
Best practices in VeDDRA coding 27 November 2013 Presented by: Giles Davis Chair of PhVWP-V VeDDRA sub-group An agency of the European Union Veterinary Dictionary for Drug Related Affairs SOC = System
More informationCoding with MedDRA 3/6/2019
Coding with MedDRA MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationIntroductory Guide MedDRA Version 18.1
Introductory Guide MedDRA Version 18.1 Notice to Reader Notice to Reader This Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory
More informationSponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1
Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy
More informationSponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination
Sponsor Alcon Research, Ltd. Generic Drug Name Travoprost/timolol maleate Trial Indications Open-angle glaucoma or ocular hypertension Protocol Number C-09-007 Protocol Title An Evaluation of Patient Reported
More informationCase Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014
- 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases
More informationINDEX FOR 3 AND 4 DIGIT DIAGNOSTIC CODES (ICD9)
INDEX FOR 3 AND 4 DIGIT DIAGNOSTIC CODES (ICD9) INFECTIONS AND PARASITIC DISEASES 001-009.3 Intestinal and Infectious Diseases 010-018.9 Tuberculosis 020-027.9 Zoonotic Bacterial Diseases 030-041.9 Other
More informationPaper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2012:
Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2012: VACCINE-ASSOCIATED SUSPECTED ADVERSE REACTIONS REPORTED VIA THE YELLOW CARD SCHEME DURING 2011 September 2012 CONTENTS
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationMedDRA: Safety Data Analysis and SMQs
MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
More informationMedDRA Coding and Versioning
MedDRA Coding and Versioning 4th ANNUAL INNOVATIONS IN CLINICAL DATA MANAGEMENT Alexandria, VA. 27-28 October 2016 Anna Zhao-Wong, MD, PhD Deputy Director of MedDRA MSSO anna.zhao-wong@meddra.org Agenda
More informationMedDRA Safety Data Analysis and SMQs
MedDRA Safety Data Analysis and SMQs MedDRA: Safety Data Analysis and SMQs MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration
More informationPatient Last Name First Name Middle Name. Home Address City State Zip. Date of Birth Age Social Security # - - Cell Phone Home Phone Work Phone
Date Patient Last Name First Name Middle Name Gender (circle): Male Female Other: Marital Status (circle): Single Married Divorced Widowed Separated Home Address City State Zip Date of Birth Age Social
More informationCardiothoracic and Cardiothoracic Surgery ICD-10-CM 2014: Reference Mapping Card
2014: Reference Mapping Card 162.3 Malignant neoplasm upper lobe lung 162.5 Malignant neoplasm lower lobe lung 162.9 lung/bronchus 396.2 396.3 Mitral insufficiency, aortic stenosis Mitral aortic valve
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationQuality of prescribing in chronic kidney disease and type 2 diabetes Smits, Kirsten Petronella Juliana
University of Groningen Quality of prescribing in chronic kidney disease and type 2 diabetes Smits, Kirsten Petronella Juliana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSynopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant
More informationENROLLMENT : Line of Business Summary
ENROLLMENT : Line of Business Summary Date Range : JAN 2017 through DEC 2017 COMPREHENSIVE MAJOR MEDICAL Print Date : 1/19/2018 9:43:49AM Page 1 of 1 Month Year Single 2 Person : Emp/Spouse 2 Person :
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationCOURSE OUTLINE Pathophysiology
Butler Community College Health, Education, and Public Services Division Denise LaKous Revised Spring 2014 Implemented Fall 2015 Textbook Update Fall 2015 COURSE OUTLINE Pathophysiology Course Description
More informationUpdate overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab
Update overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab Introduction Lareb previously published yearly overviews of reports (most recently in 2017) in consultation
More informationPronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016 ClinicalTrials.gov ID: NCT00595413 Study Identification Unique Protocol ID: 27905 Brief Title: Atacicept
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationIroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM
Iroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM PHILADELPHIA, April 8, 2015 Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the
More informationPACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG. (goserelin)
ONC.000-092-861.10.0 PACKAGE LEAFLET TEXT ZOLADEX LA 10.8MG (goserelin) Name of the medicinal product Zoladex LA 10.8mg depot Qualitative and quantitative composition Goserelin acetate (equivalent to 10.8
More informationDiagnosis-specific morbidity - European shortlist
I Certain infectious and parasitic diseases 1 Tuberculosis A15-A19 X X Z 2 Sexually transmitted diseases (STD) A50-A64 Y Z 3 Viral hepatitis (incl. hepatitis B) B15-B19 X Z 4 Human immunodeficiency virus
More informationMedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know
MedDRA 10.1 Review MedDRA Version Changes General Remarks Terminology Files: What you need to know MedDRA Version 10.1 Specific Changes Version 10.1 Changes Overview Changes in a Nutshell Changes Highlights
More informationRoutine signal detection and statistical tools on paediatrics
Routine signal detection and statistical tools on paediatrics Paediatric workshop 28 April 2014 Presented by: Cosimo Zaccaria Signal Management Pharmacovigilance Department An agency of the European Union
More informationFrom A to Z-Codes Matter
From A to Z-Codes Matter Susan Wallace, MEd, RHIA, CCS, CDIP, CCDS, FAHIMA While ALL ICD-10-CM codes are important, the Z-codes in ICD-10-CM are frequently considered step-children, supplemental codes
More informationNov FromAtoZCodesMatter
Nov 2017 FromAtoZCodesMatter From A to Z-Codes Matter Susan Wallace, MEd, RHIA, CCS, CDIP, CCDS, FAHIMA The implementation of ICD-10 brought tens of thousands of new codes. Ranging from A to Z, they portray
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections
More informationImplemented MedDRA Version 22.0 Complex Changes (October 2018)
Implemented MedDRA Version 22.0 Complex Changes (October 2018) MedDRA User Proposed Requests: 1. Move HLT Cardiac disorders NEC from HLGT Cardiac disorder signs and symptoms to new HLGT Cardiac disorders
More informationPharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:
0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013
More informationEMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit) RISK OF SERIOUS HYPERSENSITIVITY AND SKIN REACTIONS
The European Agency for the Evaluation of Medicinal Products Post-authorisation evaluation of medicines for human use London, 22 October 2002 EMEA/25175/02 EMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit)
More informationPart VI: Summary of the risk management plan by product
Version 1.3, 28-Dec-2015 Risk Management Plan of a fixed combination of Dexketoprofen trometamol and Tramadol hydrochloride (oral formulation) Part VI: Summary of the risk management plan by product VI.1
More informationOverview of reports of thromboembolic adverse drug reactions associated with cyproterone/ethinylestradiol
Overview of reports of thromboembolic adverse drug reactions associated with cyproterone/ethinylestradiol Introduction The European Medicines Agency s Pharmacovigilance Risk Assessment Committee (PRAC)
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More information0BCore Safety Profile
0BCore Safety Profile Active substance: Somatropin Pharmaceutical form(s)/strength: Powder and solvent for solution for injection, 4mg/ml, 5 mg/ml and 10 mg/ml P-RMS: FR/H/PSUR/0059/001 Date of FAR: 25.02.2013
More informationCoding with MedDRA 1
Coding with Coding with MedDRA 1 4/3/2015 Coding with MedDRA MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More information, version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Docetaxel Orion 20 mg/1 ml concentrate for solution for infusion Docetaxel Orion 80 mg/4 ml concentrate for solution for infusion Docetaxel Orion 160 mg/8 ml concentrate for solution for infusion 11.8.2014,
More informationPrioritized ShortList MORBIDITY
Report on in-depth analysis of pilot studies in 16 Member States on diagnosis-specific morbidity statistics Annex 2 (Rev 11_11_13) Prioritized ShortList MORBIDITY Legend: X recommended for collection Y
More informationMedDRA Coding Quality: How to Avoid Common Pitfalls
MedDRA Coding Quality: How to Avoid Common Pitfalls Patricia Mozzicato, MD Chief Medical Officer MedDRA MSSO Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More information